Long-acting β2-agonists (LABAs) are a staple of Chronic Obstructive Pulmonary Disease (COPD)
maintenance treatment frequently prescribed to patients for prolonged bronchodilation…

Purpose Long‐acting bronchodilators, ie beta‐2‐agonists (LABA) and tiotropium are commonly
used in COPD treatment. Choice of a specific agent is based on effectiveness and safety…

… 29.42%; p=0.043) diagnoses were lower for TIO+OLO with 24% reduced risk of experiencing
pneumonia/acute bronchitis/bronchiolitis diagnosis (adjusted HR=0.76; 95% CI: 0.60-0.97; …

… According to the GOLD therapeutic strategy, long-acting formulations of beta2-agonists
and … One study showed that patients reporting use of ≥1.5 short-acting beta2-agonists (SABA) …

… For the sample size calculation, we considered a mean duration of severe symptoms in
uncomplicated acute bronchitis of 5.5 days (SD 4.5) and a reduction of 1.5 days as a clinically …

… note that long-acting muscarinic agents/beta2-agonists (LAMA+LABA) are the preferred
first-line … with a diagnosis of COPD (or pneumonia/acute bronchitis/bronchiolitis) in any position. …

… We will report adverse effects with a focus on severe effects reported in studies of LABA
or LAMA (ie adverse cardiac events). Specifically, we will report on the following pre‐specified …

… The excessive prescribing of short-acting beta2-agonists (SABAs), an indicator of poorly
controlled asthma and a risk factor for asthma attacks, remains problematic despite proliferating …

… Acute exacerbations are now the main outcome evaluated in clinical trials as they are
associated with increased respiratory and cardiovascular mortality, long‐term decline in lung …

… according to the response to short acting beta2 agonists or the effect of a therapeutic trial …
In JPGL2017, the transdermal patch and oral beta2 agonists are positioned as drugs within …